[Comparative study of 2 chemotherapy induction protocols. Cisplatinum-methotrexate-bleomycin and oncovin-methotrexate-bleomycin].
A prospective randomized study was conducted in 77 patients with stages III and IV epidermoid carcinomas of the buccal cavity, oropharynx, and pharyngolaryngeal regions to compare effects of two induction chemotherapy regimens: cisplatinum, methotrexate, bleomycin, and oncovin, methotrexate, bleomycin. Tumoral response and complications were analyzed as a function of the regimen, the tumoral site, and the stage. Chemotherapy including cisplatinum provided a tumoral response in 58.8 p.cent of stage III pharyngolaryngeal epitheliomas as against 38.4 p.cent with oncovin, methotrexate, bleomycin, but with a higher frequency of complications.
D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009062:Mouth Neoplasms / Q000188:drug therapy; D009367:Neoplasm Staging; D010610:Pharyngeal Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects
D001761:Bleomycin; D014750:Vincristine; D002945:Cisplatin; D008727:Methotrexate
Etude comparative de deux protocoles de chimiothérapie d'induction. Cisplatinum-méthotrexate-bléomycine, oncovin-méthotrexate-bléomycin.